07.09.2017 • News

Jimenez to Quit Novartis Next Year

Novartis CEO Joseph Jimenez has announced he will leave the Swiss-based...
Novartis CEO Joseph Jimenez has announced he will leave the Swiss-based drugnaker in early 2018, after eight years at the helm, and return to his native US

Novartis CEO Joseph Jimenez has announced he will leave the Swiss-based drugnaker in early 2018, after eight years at the helm, and return to his native US. However, he will remain "available for advice and support" until his official retirement on Aug. 31, Novartis said in a statement.

Jimenez will be succeeded in Basel by another American,Vasant Narasimhan, at present chief medical officer and global head of drug development. Narasimhan joined Novartis in 2005 and has held a variety of leadership positions.

The current Novartis chief focused the drugmaker on leading global businesses, while divesting non-core divisions, supervisory board chairman Joerg Reinhardt said. "Under his leadership the innovation pipeline was rejuvenated, and we successfully navigated the patent expirations of our two largest products."

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

most read